AstraZeneca PLC announced that FluMist, a nasal spray flu vaccine, received FDA approval on September 20, 2024, for self-administration by adults up to 49 years and caregiver administration for ages 2-17, enhancing access to vaccination. This approval aims to address declining vaccination rates in adults, with an estimated 31 million influenza cases the last season, highlighting the need for at-home options.